| Patrick Fink, MD | |
|
1253 Nw Canal Blvd, Redmond, OR 97756-1334 | |
| (541) 548-8131 | |
| (541) 460-4028 |
| Full Name | Patrick Fink |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 6 Years |
| Location | 1253 Nw Canal Blvd, Redmond, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194258954 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 11410741-1205 (Utah) | Secondary |
| 207P00000X | Emergency Medicine | MD213509 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Charles Medical Center - Bend | Bend, OR | Hospital |
| St Charles Madras | Madras, OR | Hospital |
| St Charles Prineville | Prineville, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Charles Health System Inc | 3870402852 | 150 |
News Archive
"The International AIDS Society (IAS), custodian of the International AIDS Conference, and the Kaiser Family Foundation will provide free, worldwide online access to the XIX International AIDS Conference (AIDS 2012) taking place in Washington, D.C.," from July 22 to 27, a joint Kaiser/IAS press release reports.
University of Oregon scientists have discovered how the bacterium Helicobacter pylori navigates through the acidic stomach, opening up new possibilities to inactivate its disease-causing ability without using current strategies that often fail or are discontinued because of side effects.
Sugar is a vital source of energy for both plants and animals alike. Understanding just how sugar makes its way into the cell could lead to the design of better drugs for diabetes patients and an increase in the amount of fruits and vegetables farmers are able to grow.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
› Verified 2 days ago
| Entity Name | St Charles Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982621447 PECOS PAC ID: 3870402852 Enrollment ID: O20040112000045 |
News Archive
"The International AIDS Society (IAS), custodian of the International AIDS Conference, and the Kaiser Family Foundation will provide free, worldwide online access to the XIX International AIDS Conference (AIDS 2012) taking place in Washington, D.C.," from July 22 to 27, a joint Kaiser/IAS press release reports.
University of Oregon scientists have discovered how the bacterium Helicobacter pylori navigates through the acidic stomach, opening up new possibilities to inactivate its disease-causing ability without using current strategies that often fail or are discontinued because of side effects.
Sugar is a vital source of energy for both plants and animals alike. Understanding just how sugar makes its way into the cell could lead to the design of better drugs for diabetes patients and an increase in the amount of fruits and vegetables farmers are able to grow.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
› Verified 2 days ago
| Entity Name | Central Oregon Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376714543 PECOS PAC ID: 6406926211 Enrollment ID: O20080605000639 |
News Archive
"The International AIDS Society (IAS), custodian of the International AIDS Conference, and the Kaiser Family Foundation will provide free, worldwide online access to the XIX International AIDS Conference (AIDS 2012) taking place in Washington, D.C.," from July 22 to 27, a joint Kaiser/IAS press release reports.
University of Oregon scientists have discovered how the bacterium Helicobacter pylori navigates through the acidic stomach, opening up new possibilities to inactivate its disease-causing ability without using current strategies that often fail or are discontinued because of side effects.
Sugar is a vital source of energy for both plants and animals alike. Understanding just how sugar makes its way into the cell could lead to the design of better drugs for diabetes patients and an increase in the amount of fruits and vegetables farmers are able to grow.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Patrick Fink, MD Po Box 6095, Bend, OR 97708-6095 Ph: (541) 706-5922 | Patrick Fink, MD 1253 Nw Canal Blvd, Redmond, OR 97756-1334 Ph: (541) 548-8131 |
News Archive
"The International AIDS Society (IAS), custodian of the International AIDS Conference, and the Kaiser Family Foundation will provide free, worldwide online access to the XIX International AIDS Conference (AIDS 2012) taking place in Washington, D.C.," from July 22 to 27, a joint Kaiser/IAS press release reports.
University of Oregon scientists have discovered how the bacterium Helicobacter pylori navigates through the acidic stomach, opening up new possibilities to inactivate its disease-causing ability without using current strategies that often fail or are discontinued because of side effects.
Sugar is a vital source of energy for both plants and animals alike. Understanding just how sugar makes its way into the cell could lead to the design of better drugs for diabetes patients and an increase in the amount of fruits and vegetables farmers are able to grow.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
› Verified 2 days ago
Catherine Elizabeth Fairgrieve Appel, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1253 Nw Canal Blvd, Redmond, OR 97756 Phone: 541-548-8131 Fax: 541-526-6608 | |
Glynda Gaye Crabtree, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1253 Nw Canal Blvd, Redmond, OR 97756 Phone: 541-548-8131 Fax: 253-838-6418 | |
Andrew Stokes Kleaveland, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1253 Nw Canal Blvd, Redmond, OR 97756 Phone: 541-548-8131 Fax: 541-460-4028 | |
Mindy Lipsitz, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1253 Nw Canal Blvd, Redmond, OR 97756 Phone: 541-548-8131 Fax: 541-526-6608 | |
Angus Yatman Ng, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1253 Nw Canal Blvd, Redmond, OR 97756 Phone: 541-548-8131 Fax: 541-526-6608 | |
Jake Metolius Waits, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1253 Nw Canal Blvd, Redmond, OR 97756 Phone: 541-548-8131 Fax: 541-526-6608 | |
Matthew M Eschelbach, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1253 Nw Canal Blvd, Redmond, OR 97756 Phone: 541-548-8131 Fax: 541-526-6608 |